Sign In
Buy MNPR
$81.77
+13.11 (+19.09%)
At Close: Jun 23, 2026
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade
10:55am, Monday, 15'th Jun 2026
The mean of analysts' price targets for Monopar Therapeutics (MNPR) points to an 88.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatm
WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatme
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
02:00pm, Thursday, 14'th May 2026
WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treat
WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treat
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
01:00pm, Friday, 27'th Mar 2026
WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovati
Monopar Therapeutics Inc. $MNPR Shares Acquired by Ally Bridge Group NY LLC
03:31am, Sunday, 15'th Mar 2026
Ally Bridge Group NY LLC increased its position in shares of Monopar Therapeutics Inc. (NASDAQ: MNPR) by 86.6% in the undefined quarter, according to its most recent disclosure with the Securities and
WILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical‐stage biopharmaceutical company developing innovative tre
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
11:16am, Monday, 22'nd Dec 2025
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
Monopar Therapeutics (NASDAQ:MNPR) Shares Gap Down After Earnings Miss
02:40am, Saturday, 15'th Nov 2025
Shares of Monopar Therapeutics Inc. (NASDAQ: MNPR - Get Free Report) gapped down prior to trading on Friday following a weaker than expected earnings announcement. The stock had previously closed at $
Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments
08:00am, Thursday, 13'th Nov 2025
WILMETTE, Ill., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative trea
WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatm
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Rating of “Buy” by Analysts
01:31am, Sunday, 26'th Oct 2025
Monopar Therapeutics Inc. (NASDAQ: MNPR - Get Free Report) has been given an average rating of "Buy" by the eleven research firms that are currently covering the company, Marketbeat Ratings reports. O
Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect?
10:56am, Tuesday, 21'st Oct 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 42.5% in Monopar Therapeutics (MNPR). While the effectiveness of this highly sought-after metric is questionabl
Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025
08:00am, Wednesday, 15'th Oct 2025
WILMETTE, Ill., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatm
